secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0000950170-22-016457
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics Q2 2022 net loss $28.4M; cash $180.9M; IND submissions on track
--------------------------------------------------------------------------------

- Net loss $28.4M ($0.69 per share); R&D expense $20.9M; G&A expense $7.7M.
- Cash, equivalents and marketable securities $180.9M; expected to fund operations into H2 2023.
- IND submissions for TN-201 (MYBPC3) and TN-301 (HDAC6) remain on track for H2 2022.
- Manufacturing facility in Union City launched, state-licensed for cGMP drug product at 1000L scale.
- Preclinical data presented on TN-401 (PKP2 gene therapy) and novel AAV capsids improving cardiac tropism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022016457/0000950170-22-016457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022016457/tnya-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer